These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29076054)

  • 1. Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.
    Lucchesi S; Marcianò I; Panagia P; Intelisano R; Randazzo MP; Sgroi C; Altavilla G; Santarpia M; Adamo V; Franchina T; Ferraù F; Reitano P; Trifirò G
    Clin Drug Investig; 2018 Mar; 38(3):269-278. PubMed ID: 29076054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy.
    Marcianò I; Randazzo MP; Panagia P; Intelisano R; Sgroi C; Ientile V; Cannavò S; Guarneri C; Reitano P; Spina E; Trifirò G
    G Ital Dermatol Venereol; 2020 Aug; 155(4):441-451. PubMed ID: 29582617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
    Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
    BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biosimilars: opportunities and risks].
    Grieshaber-Bouyer R; Lorenz HM
    Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.
    Trifirò G; Isgrò V; Ingrasciotta Y; Ientile V; L'Abbate L; Foti SS; Belleudi V; Poggi F; Fontana A; Moretti U; Lora R; Sabaini A; Senesi I; Sorrentino C; Puzo MR; Padula A; Fusco M; Giordana R; Solfrini V; Puccini A; Rossi P; Del Zotto S; Leoni O; Zanforlini M; Ancona D; Bavaro V; Garau D; Ledda S; Scondotto S; Allotta A; Tuccori M; Gini R; Bucaneve G; Franchini D; Cavazzana A; Biasi V; Spila Alegiani S; Massari M;
    BioDrugs; 2021 Nov; 35(6):749-764. PubMed ID: 34637126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
    Lyman GH
    J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
    [No Abstract]   [Full Text] [Related]  

  • 11. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
    Marcianò I; Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Di Giorgio A; Manna S; Ientile V; Gini R; Santarpia M; Genazzani AA; Uomo I; Pastorello M; Pollina Addario SW; Scondotto S; Cananzi P; Da Cas R; Traversa G; Rossi M; Sottosanti L; Caputi AP; Trifirò G
    BioDrugs; 2016 Aug; 30(4):295-306. PubMed ID: 27138636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
    Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Tari DU; Troncone C; Fontana A; Ientile V; Gini R; Santoro D; Santarpia M; Genazzani A; Uomo I; Pastorello M; Addario WS; Scondotto S; Cananzi P; Caputi AP; Trifirò G
    BioDrugs; 2015 Aug; 29(4):275-84. PubMed ID: 26169209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?
    Ingrasciotta Y; Sultana J; Formica D; Ientile V; Aiello A; Chinellato A; Tari DU; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Rossi M; Santoro D; Trifirò G;
    Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):65-77. PubMed ID: 33067914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
    Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
    Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases.
    Gils A; Bertolotto A; Mulleman D; Bejan-Angoulvant T; Declerck PJ
    Ther Drug Monit; 2017 Aug; 39(4):308-315. PubMed ID: 28230618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in oncology: Effects on economy and therapeutic innovations.
    Hübel K; Kron F; Lux MP
    Eur J Cancer; 2020 Nov; 139():10-19. PubMed ID: 32950935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
    Zheng MK; Shih DQ; Chen GC
    World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.